Synergistic effect of the novel β-lactamase inhibitor BLI-489 combined with imipenem or meropenem against diverse carbapenemase-producing carbapenem-resistant Enterobacterales.

Shiyi ShiXiaodong ZhangZhuocheng YaoMengxin XuBeibei ZhouQi LiuYing ZhangCui ZhouZhexiao MaJianzhong Ye

Published in: The Journal of antimicrobial chemotherapy (2022)

The novel β-lactamase inhibitor BLI-489 possesses a synergistic effect against diverse carbapenemase-producing CRE combined with imipenem or meropenem.

Keyphrases

gram negative
klebsiella pneumoniae
multidrug resistant
escherichia coli
acinetobacter baumannii
drug resistant
pseudomonas aeruginosa